The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Reducing the duration of androgen-deprivation therapy (ADT) with radiation therapy (RT) from 36 months to 18 months is safe and may represent a new standard of care for patients with high-risk prostate cancer (HRPC), according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

The phase 3 study (ClinicalTrials.gov Identifier: NCT00223171) compared 3 years of ADT given with pelvic and prostate irradiation with 18 months of a similar treatment strategy. Three-year ADT plus RT was considered the standard care for men with HRPC (T3 to T4 disease, PSA greater than 7 ng/mL, Gleason score greater than 7).

Of the 630 men enrolled, 310 received 36 months of therapy and 320 men received 18 months of therapy.

Baseline demographics and disease characteristics were similar across the 2 arms of the study.

After a median follow up of 9.4 years, 10-year OS was 62.4% for men receiving 36 months of ADT therapy and 62.0% for men receiving 18 months of therapy. With a hazard ratio of 1.024, the difference was not significant (P = .8411).

A quality of life (QoL) analysis showed significant difference for men receiving 18 months of ADT therapy vs 36 months.

The authors concluded that “in HRPC, ADT combined with RT can be safely reduced from 36 to 18 months without compromising outcomes or QoL. 18 months of ADT represents a new standard of care in HRPC.”

RELATED: aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Nabid A, Garant MP, Martin AG, et al. Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial. J Clin Oncol. 2017;35(suppl; abstr 5008).